Skip to content

A trial to explore the effectiveness of siddha treatment for pakkavatham ( Hemiplegic stroke)

A Pilot clinical trial to explore the effectiveness of selected Siddha treatment instituted for Pakka vatham (Subacute and Chronic Ischemic Hemiplegic Stroke) at Ayothidoss Pandithar Hospital, NIS. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057216
Enrollment
10
Registered
2023-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G819- Hemiplegia, unspecified

Interventions

Intervention1: DRUG: Kadikara chenduram 30 mg bd and amukkara chooranam 3 gm bd with honey DRUG DURATION: 7 days DRUD HOLIDAY: 5 days The course will be repeated for 7 times (80 days) These medicines

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 – 70 years. Ischemic stroke confirmed by brain magnetic resonance imaging or computed tomography. Patients who have had a stroke for 3 months and above. Those who have Hemiplegia after a stroke. If the walking pattern is abnormal and the walking speed is less than 0.8m / sec. Modified Ranking scale (mRS) scores 3-5 at the time of enrolment. Pre-stroke modified Rankin scale (mRS) less than or equal to 2. The patients who understand the research and have voluntary participation.

Exclusion criteria

Exclusion criteria: Neurological conditions other than stroke like Guillian-barre syndrome, Chronic Inflammatory demyelinating polyradiculopathy, Parkinson’s disease, Transverse myelitis. Patient who had stroke incidence before 1 year. Patient without intact higher mental function and cognition assessed by MOCA scale . Patients with grade 3 arthritis and traumatic injuries and Traumatic Brain Injuries. Other chronic disabling pathologies orthopedic injuries that could impair locomotion. Participating in other clinical trial within 30 days prior screening. History of major depressive or other severe psychiatric disorders. Current concomitant institution of traditional and/or complementary treatments for other or same condition.

Design outcomes

Primary

MeasureTime frame
Proportion of patients who would have Minimal Clinically Important Difference (MICD) in the kinematic motor function assessed through FUGL MEYER scoring from baseline to endpoint.Timepoint: Baseline 0 day 20th day 40th day End point 80th day

Secondary

MeasureTime frame
Comparing the degree of difference in disability using Modified Rankin Score (mRS) from baseline to end point. Comparing the improvement in the walking speed, functional mobility, gait & vestibular functions with the intervention using 10 Meter-walk test & 6-minute walk test score from baseline to end point. Comparing improvement with intervention in balance while attempting the tasks using Postural Assessment Scale for Stroke patients (PASS) from baseline to end point. Comparing improvement of Speech apraxia using Apraxia Speech Rating Scale (ASRS). Comparing assess the improvement in the degree of disability with intervention using Modified Rankin Score (mRS) from baseline to end point. Comparing the improvement with intervention in Quality of life using Stroke Impact Scale (SIS) & Patient health Questionnaire for Anxiety & Depression (PHQ -4) at baseline & endpoint. Timepoint: Base line O day 20th day 40th day End point 80th day

Countries

India

Contacts

Public ContactProf Dr G J Christian

NATIONAL INSTITUTE OF SIDDHA

christianvijila@gmail.com9962545930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026